Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Adverum Biotechnologies, Inc. to Eli Lilly and Company for Adverum shareholders, focusing on the adequacy of the offered compensation and the board's fiduciary duties [1][3]. Group 1: Transaction Details - Adverum shareholders are set to receive $3.56 per share in cash, along with a non-transferrable contingent value right (CVR) that could yield up to an additional $8.91 per CVR upon achieving specific milestones [1]. Group 2: Legal Investigation - The investigation aims to determine if Adverum and its board violated federal securities laws or breached fiduciary duties by not securing the best possible consideration for shareholders, assessing whether Eli Lilly is underpaying, and failing to disclose all material information necessary for shareholders to evaluate the merger [3]. Group 3: Potential Actions - Halper Sadeh LLC may pursue increased compensation for shareholders, additional disclosures, and other forms of relief related to the proposed transaction [4].

Accessibility StatementSkip Navigation NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: h ...

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics. Investors have until December 15, 2025, to ask the Court to be app ...

Core Insights - Eli Lilly and Company has announced a definitive agreement to acquire Adverum Biotechnologies, Inc., focusing on the gene therapy Ixo-vec for treating wet age-related macular degeneration (wAMD) [1][2][4] Company Overview - Eli Lilly is a long-established pharmaceutical company with a focus on innovative medicines for chronic and age-related conditions, leveraging biotechnology and genetic medicine [10] - Adverum Biotechnologies is a clinical-stage company developing gene therapies aimed at restoring vision and preventing blindness, particularly through its lead product candidate, Ixo-vec [11] Product Details - Ixo-vec is a Phase 3 gene therapy designed for a one-time treatment of wAMD, aiming to deliver stable intraocular aflibercept levels and reduce the burden of current chronic therapies [2][12] - The therapy has received multiple designations from regulatory agencies, including Fast Track and RMAT from the FDA, and PRIME from the EMA, indicating its potential significance in treating wAMD [3][13] Acquisition Terms - Under the merger agreement, Lilly will offer $3.56 per share in cash for Adverum's common stock, plus a contingent value right (CVR) that could provide up to an additional $8.91 per share based on specific milestones [4][5] - The CVR includes payments contingent on U.S. approval of Ixo-vec and achieving annual worldwide net sales exceeding $1 billion [5][6] Financial Support - Adverum will receive a Promissory Note from Lilly for up to $65 million to support ongoing clinical trials for Ixo-vec, with conditions tied to the acquisition's closing [7][8] Strategic Rationale - The acquisition aligns with Lilly's strategy to enhance its genetic medicine capabilities and expand the potential of gene therapy in addressing age-related diseases [1][4] - Adverum's board unanimously approved the merger after evaluating various strategic alternatives, indicating confidence in the partnership's potential benefits [8]

My last coverage of Crispr Therapeutics (NASDAQ: CRSP ) and Intellia Therapeutics (NASDAQ: NTLA ) was published in May 2025 . At the time, gene therapy stocks were suffering from regulatory uncertainties, potential pricingOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in life sciences to assess the potential o ...

ADC Therapeutics (NYSE:ADCT) is one of the best long term penny stocks with huge upside potential. On October 16, H.C. Wainwright analyst Robert Burns lowered the price target on ADC Therapeutics to $7 from $8 and maintained a Buy rating on the shares. The firm reduced the price target after factoring in the private placement financing. H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement In other news, earlier on October 12, DC Therapeutics announced a $60 million pri ...

SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 10, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeu ...

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjögren’s disease, systemic lupus erythematosus, and rheumatoid arthritis Poster presentation on October 26th at 10:30 am CDT BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nas ...

Core Viewpoint - Qualigen Therapeutics Inc. has partnered with BitGo to enhance its cryptocurrency treasury strategy, leading to a significant surge in its stock price during after-hours trading [1][2]. Group 1: Stock Performance - Qualigen shares increased by over 60% in after-hours trading, building on a 5.37% gain during the regular trading session, closing at $3.530 [2][4]. - Year-to-date, the stock has decreased by 16.15%, but recent trends indicate a stronger price momentum in the short and medium term [4]. Group 2: Partnership Details - The partnership with BitGo allows Qualigen to manage a diversified investment across the top 10 cryptocurrencies, utilizing BitGo's over-the-counter desk [3]. - BitGo will provide custody and liquidity services for Qualigen's digital assets, ensuring they are stored in regulated cold storage with compliance protocols [3]. Group 3: Company Background - Qualigen is majority-owned by Faraday Future Intelligent Electric Inc., indicating a strategic alignment with a company in the electric vehicle sector [3].

STOCKHOLM, Sweden, October 24, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented positive results from a preclinical study of its immunotherapy SVF-001 targeting chronic hepatitis B and D at the Molecular Biology of HBV meeting in Berlin and the DeltaCure meeting in Hannover. SVF Vaccines develops DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. In recent months, positive results fr ...